1. Adelaide Research & Scholarship

Search


Current filters:
Start a new search
Add filters:

Use filters to refine the search results.

 | 
Results 11-20 of 171 (Search time: 0.007 seconds).
Item hits:
PreviewIssue DateTitleAuthor(s)
2002Mannose-binding lectin gene polymorphisms are associated with major infection following allogeneic hemopoietic stem cell transplantationMullighan, C.; Heatley, S.; Doherty, K.; Szabo, F.; Grigg, A.; Hughes, T.; Schwarer, A.; Szer, J.; Tait, B.; To, L.; Bardy, P.
2010Mutation analysis of BCR-ABL tyrosine kinase domain in new chronic phase-chronic myeloid leukemia patients with suboptimal response or treatment failure from imatinib treatmentKim, D.; Kim, D.; Kim, S.; Goh, H.; Pane, F.; Hughes, T.; Radich, J.; Lin, P.; Saglio, G.; Branford, S.; Martinelli, G.; Soverini, S.; Hochhaus, A.; American Society of Hematology Meeting (52nd : 2010 : Florida, CA.)
1995A direct analysis of FACS-sorted hemopoietic cell fractions using fishWhite, D.; Hutchins, C.; Haylock, D.; Turczynowics, S.; Bishop, A.; To, L.; Hughes, T.; Juttner, C.
2002Juxtamembrane mutant V560GKit is more sensitive to Imatinib (STI571) compared with wild-type c-kit whereas the kinase domain mutant D816VKit is resistantFrost, M.; Ferrao, P.; Hughes, T.; Ashman, L.
2003Imatinib produces significantly superior molecular responses compared to interferon alfa plus cytarabine in patients with newly diagnosed chronic myeloid leukemia in chronic phaseBranford, S.; Rudzki, Z.; Harper, A.; Grigg, A.; Taylor, K.; Durrant, S.; Arthur, C.; Browett, P.; Schwarer, A.; Ma, D.; Seymour, J.; Bradstock, K.; Joske, D.; Lynch, K.; Gathmann, I.; Hughes, T.
2010A Review of Mutation Analysis In the TOPS Trial of Standard Dose Versus High Dose IM In CML Suggests That Refinements to the ELN Recommendations for Mutation Screening May Be AppropriateBranford, S.; Goh, H.; Izzo, B.; Beppu, L.; Ortmann, C.; Duniec, K.; Jin, Y.; Woodman, R.; Pane, F.; Kim, D.; Radich, J.; Hughes, T.; American Society of Hematology Meeting (52nd : 2010 : Florida, CA.)
2010Detection of low level nilotinib or dasatinib resistant BCR-ABL mutations by mass spectrometry in CML patients who fail Imatinib is highly predivtive of their subsequent clonal expansion when treated with the drug for which their mutation confers resistanceParker, W.; Ho, M.; Lawrence, R.; Irwin, D.; Scott, H.; Hughes, T.; Branford, S.; American Society of Hematology Meeting (52nd : 2010 : Florida, CA.)
1997Inhibition of GM-CSF prevents dissemination and induces remission of human juvenile myelomonocytic leukemia in engrafted immunodeficient mice.Iversen, P.; Lewis, I.; Turczynowicz, S.; Hasle, H.; Niemeyer, C.; Schmiegelow, K.; Bastiras, S.; Biondi, A.; Hughes, T.; Lopez, A.
2002High frequency of point mutations clustered within the adenosine triphosphate-binding region of BCR/ABL in patients with chronic myeloid leukemia or Ph-positive acute lymphoblastic leukemia who develop imatinib (STI571) resistanceBranford, S.; Rudzki, Z.; Walsh, S.; Grigg, A.; Arthur, C.; Taylor, K.; Herrmann, R.; Lynch, K.; Hughes, T.
1997Mobilization of predominantly Philadelphia chromosome-negative blood progenitors using cyclophosphamide and rHUG-CSF in early chronic-phase chronic myeloid leukaemia: correlation with Sokal prognostic index and haematological control.Hughes, T.; Grigg, A.; Szer, J.; Ho, J.; Ma, D.; Dale, B.; Green, R.; Norman, J.; Sage, R.; Herrmann, R.; Cannell, P.; Schwarer, A.; Taylor, K.; Atkinson, K.; Arthur, C.

Discover